Clinical Toolkit

  • Levodopa or L-Dopa is one of the most common Parkinson's Disease drugs. It is usually one of the first medications prescribed at the onset of Parkinson's Disease. It basically works by increasing dopamine levels.

  • Dopamine Agonists- An agonist is a molecule that binds to a part of a cell and initiates cell activity. Dopamine agonists directly stimulate dopamine receptors. This means that the patient's brain no longer has to depend on the degenerating nerve cells to stimulate these receptors.

  • COMT (cathecol-O-methyltransferase) Inhibitors - COMT will increase the bioavailability of L-Dopa. Metabolic reactions allow only 1% of an Levodopa taken in pill form to reach the brain. Other substances also compete with Levodopa for absorption in the gut.

An Introduction to Diabetic Retinopathy

The PD Thrive website and application are designed to offer practical, valuable, and unbiased information covering several facets of Parkinson’s disease, including epidemiology and pathophysiology, and a detailed review of current data on the safety, efficacy, and use of medical therapy for PD. This multicomponent program features both live and online activities for providers and their patients. Our objectives for the program are to educate clinicians and patients so they can:

  • Describe the difficult-to-treat symptoms associated with advanced PD
  • Review the mechanisms of action and clinical profiles of interventional therapeutic approaches for PD
  • Discuss the impact of approved and investigational agents on response rates and quality of life
  • Explore the challenges of evaluating current data
  • Discuss how to individualize therapies
  • Discuss the benefits of a multidisciplinary team-based approach to the management of patients with PD
  • Explore methods for enhancing communication between health care providers and patients to empower patients in their own health care

By providing useful information about existing and emerging therapeutic options, we hope to provide a beneficial learning environment for our learners, with the ultimate goal of improving care for each individual patient.

References

  1. Diabetic retinopathy factsheet. https://www.cdc.gov/visionhealth/pdf/factsheet.pdf. Accessed November 27, 2019.
  2. National Eye Institute (NEI). Diabetic retinopathy. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/diabetic-retinopathy. Accessed December 3, 2019.
  3. CDC Vision Health Initiative. Diabetic retinopathy. https://www.cdc.gov/visionhealth/publications/diabetic_retinopathy.htm. Accessed November 27, 2019.
  4. Opere CA, O’Brien KK, Shea JL. Understanding diabetic retinopathy. US Pharm. 2011;36:46-52.
  5. Cheung N, Mitchell P, Wong T. Diabetic retinopathy. Lancet. 2010;376:124-136.

Parkinsons

Copyright © 2019 | Thrive Parkinsons | All Rights Reserved | Website by Divigner

Patient Toolkit

The THRIVE Patient Toolkit is a resource center for patients who received diagnosis of or who are interested in learning about Parkinson’s disease. Choose from the options below to learn more.

Clinical Toolkit

The THRIVE Clinical Toolkit is an online tool that aims to provide clinicians up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for Parkinson’s disease. Click on one of the options below to learn more about PD.

This activity is supported by an independent medical education grant from AbbVie.

Copyright © 2019 | Diabetic Retinopathy | All Rights Reserved | Website by Divigner